He led development of a new systems pharmacology platform to predict unexpected drug activities and side effects, the Similarity Ensemble Approach. His lab investigates how small molecules strike “chords” of multiple targets at once to perturb cellular and disease networks. A major focus of this work is on the discovery of chords for neurodegenerative diseases, where therapeutics acting through polypharmacology may enable entirely novel treatment routes. Previously, Dr. Keiser co-founded a start-up company, after training at UCSF and Stanford University. Dr. Keiser has recently been selected for a Glenn Award for Research in the Biological Mechanisms of Aging.